MDNAF - New Buy Medicenna: Superkine Platform In Oncology

2024-05-07 17:17:19 ET

Summary

• Medicenna is a Canadian biotech company developing Superkines, enhanced cytokine drugs, in oncology.
• Their lead asset, MDNA-11, showed promising results in a Phase 1/2 study for refractory cancers, including a monotherapy partial response in pancreatic cancer.
• Bizaxofusp, an IL-4 Superkine, demonstrated compelling results in glioblastoma, with increased median overall survival compared to the control arm.
• The company will present the updated data from MDNA-111 monotherapy cohorts and combination cohorts (with Keytruda) for the Phase 1/2 Abilify study at in advanced/metastatic refractory solid tumors at the upcoming ASCO conference in June.

Medicenna Therapeutics Corp. ( MDNAF , MDNA.CA) is a Canadian biotech company that is developing Superkines (enhanced cytokine drugs) in oncology....

For further details see: